Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$0.38 - $0.68 $1,520 - $2,720
4,000 Added 15.38%
30,000 $12,000
Q4 2023

Feb 06, 2024

BUY
$0.37 - $1.07 $5,885 - $17,021
15,908 Added 157.63%
26,000 $17,000
Q3 2023

Oct 23, 2023

SELL
$0.37 - $2.85 $17,717 - $136,475
-47,886 Reduced 82.59%
10,092 $4,000
Q2 2023

Aug 10, 2023

BUY
$1.52 - $2.8 $7,600 - $14,000
5,000 Added 9.44%
57,978 $155,000
Q3 2022

Nov 14, 2022

BUY
$0.24 - $30.3 $720 - $90,900
3,000 Added 6.0%
52,978 $102,000
Q1 2022

May 04, 2022

BUY
$21.3 - $39.0 $163,392 - $299,169
7,671 Added 18.13%
49,978 $103,000
Q4 2021

Jan 31, 2022

BUY
$25.65 - $46.05 $662,154 - $1.19 Million
25,815 Added 156.53%
42,307 $82,000
Q3 2021

Oct 29, 2021

BUY
$42.6 - $58.65 $702,559 - $967,255
16,492 New
16,492 $51,000

About BioCardia, Inc.


  • Ticker BCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,758,200
  • Market Cap $39.8M
  • Description
  • BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary di...
More about BCDA
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.